A Phase II Study for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma
NCT01929265
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
73
Enrollment
OTHER
Sponsor class
Conditions
Indolent Non-follicular
Non-Hodgkin's Lymphoma
Interventions
DRUG:
Bendamustine
Sponsor
Fondazione Italiana Linfomi - ETS